Generated by AI
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune and inflammatory diseases driven by immune system dysfunction. The company’s current programs center on restoring healthy immune balance through targeted modulation of the adaptive and innate immune systems, with a lead emphasis on treatments for alopecia areata and other immune-mediated conditions. Q32 Bio’s pipeline includes bempikibart, an antibody-based candidate designed to regulate immune signaling in dermatology and related autoimmune settings, as well as research efforts in complement-pathway biology for tissue-targeted immune control. The company’s work is positioned within the broader biopharmaceutical sector, where precision immunology and biologics play an important role in addressing chronic diseases with limited treatment options. Based in Waltham, Massachusetts, Q32 Bio continues to operate as a research-focused company advancing specialized therapies from clinical development programs.
Website830 Winter Street
Waltham, MA, 02451
United States
The latest articles about QTTB.
Summary of Sep 30's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
No summary yet.
Summary of Sep 30's posts. Generated by AI.
Investors talking about QTTB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.